Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.17179/excli2020-1189

http://scihub22266oqcxt.onion/10.17179/excli2020-1189
suck pdf from google scholar
32210741!7081067!32210741
unlimited free pdf from europmc32210741    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid32210741
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target #MMPMID32210741
  • Ortega JT; Serrano ML; Pujol FH; Rangel HR
  • EXCLI J 2020[]; 19 (ä): 400-409 PMID32210741show ga
  • Direct-acting antivirals are effective tools to control viral infections. SARS-CoV-2 is a coronavirus associated with the epidemiological outbreak in late 2019. Previous reports showed that HIV-1 protease inhibitors could block SARS-CoV main protease. Based on that and using an in silico approach, we evaluated SARS-CoV-2 main protease as a target for HIV-1 protease inhibitors to reveal the structural features related to their antiviral effect. Our results showed that several HIV inhibitors such as lopinavir, ritonavir, and saquinavir produce strong interaction with the active site of SARS-CoV-2 main protease. Furthermore, broad library protease inhibitors obtained from PubChem and ZINC (www.zinc.docking.org) were evaluated. Our analysis revealed 20 compounds that could be clustered into three groups based on their chemical features. Then, these structures could serve as leading compounds to develop a series of derivatives optimizing their activity against SARS-CoV-2 and other coronaviruses. Altogether, the results presented in this work contribute to gain a deep understanding of the molecular pharmacology of SARS-CoV-2 treatment and validate the use of protease inhibitors against SARS-CoV-2.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    400 ä.19 2020